Professional Documents
Culture Documents
Edited by:
Viive Maarika Howell, University of
Sydney, Australia
Reviewed by:
Tamara Louise Kalir, Mount Sinai
School of Medicine, USA
Janice Kwon, The University of British
Columbia, Canada
*Correspondence:
Gillian Mitchell , Familial Cancer
Centre, Peter MacCallum Cancer
Centre, Locked Bag 1, ABeckett
Street, Melbourne, VIC 8006,
Australia
e-mail: gillian.mitchell@petermac.org
www.frontiersin.org
collected systematically. Furthermore, many familial cancer clinics follow up mutation carriers and would also be in a position to
contribute prospective outcome data in the future. Provided that
all of these groups can be brought together to pool data, an answer
may be forthcoming.
So, what to advise a young BRCA mutation carrier who has
completed her family while still in her 30s, or is in her 40s and
declines RRBSO? Careful counseling is necessary to ensure that she
is fully informed about the range of surgical prevention options,
explaining the risks, and benefits, of all surgical approaches. It is
necessary to emphasize the known mortality and breast cancer
risk reduction benefits of RRBSO, and ensure that she is aware
of the range of strategies to manage any sequelae arising from a
premature surgical menopause. The advantage of the alternative
of a staged procedure starting with bilateral salpingectomy then
a bilateral oophorectomy at or approaching the age of natural
menopause is that it avoids morbidity of premature menopause
but this comes at the cost of uncertain impact on overall mortality, ovarian cancer-specific mortality and abrogation, or complete
loss of breast cancer risk reduction. The Markov model (18) concluding that RRBS with delayed RRBO salpingectomy followed
by delayed oophorectomy yields the highest quality-adjusted life
expectancy (18) is intriguing, however, it is essential for a fully
informed decision that it is made clear to the high-risk woman
that no prospective data yet exists on the efficacy of bilateral salpingectomy in reducing mortality in high-risk women. However, in
the end, it is a womans decision based on her own preferences and
life experiences and it is the role of her medical team to support
her in her choices in order to maximize their benefit and minimize their risk. Some prophylactic surgery in the form of bilateral
salpingectomy is probably better than no surgery in this high-risk
population.
AUTHOR CONTRIBUTIONS
Tess Schenberg and Gillian Mitchell, article concept, article
drafting, and final approval of manuscript.
REFERENCES
1. Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, et al. Cancer risks
for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of
EMBRACE. J Natl Cancer Inst (2013) 105(11):81222. doi:10.1093/jnci/djt095
2. National Comprehensive Cancer Network (NCCN). Genetic/High-Risk familial Assessment: Breast and Ovarian 2013. (Vol. 4). (2013). [Available from:
http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf
3. National Institute of Health and Care Excellence (NICE). Familial Breast Cancer:
Classification and Care of People at Risk of Familial Breast Cancer and Management of Breast Cancer and Related Risks in People with a Family History
of Breast Cancer. London: National Institute for Health and Care Excellence
(2013). [Available from: http://www.nice.org.uk/nicemedia/live/14188/64204/
64204.pdf
4. Rosenthal AN, Fraser L, Manchanda R, Badman P, Philpott S, Mozersky J, et al.
Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening
schedule. J Clin Oncol (2013) 31(1):4957. doi:10.1200/JCO.2011.39.7638
5. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with
cancer risk and mortality. JAMA (2010) 304(9):96775. doi:10.1001/jama.2010.
1237
6. Finch A, Narod SA. Quality of life and health status after prophylactic salpingooophorectomy in women who carry a BRCA mutation: A review. Maturitas
(2011) 70(3):2615. doi:10.1016/j.maturitas.2011.08.001
www.frontiersin.org
26. Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, et al. The
tubal fimbria is a preferred site for early adenocarcinoma in women with
familial ovarian cancer syndrome. Am J Surg Pathol (2006) 30(2):2306.
doi:10.1097/01.pas.0000180854.28831.77
27. Salvador S, Rempel A, Soslow RA, Gilks B, Huntsman D, Miller D. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and
frequent monoclonality of synchronous ovarian and fallopian tube mucosal
serous carcinoma. Gynecol Oncol (2008) 110(3):40817. doi:10.1016/j.ygyno.
2008.05.010
28. OShannessy DJ, Jackson SM, Twine NC, Hoffman BE, Dezso Z, Agoulnik SI,
et al. Gene expression analyses support fallopian tube epithelium as the cell
of origin of epithelial ovarian cancer. Int J Mol Sci (2013) 14(7):13687703.
doi:10.3390/ijms140713687
29. Antoniou AC, Rookus M, Andrieu N, Brohet R, Chang-Claude J, Peock S,
et al. Reproductive and hormonal factors, and ovarian cancer risk for BRCA1
and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev (2009) 18(2):60110.
doi:10.1158/1055-9965.EPI-08-0546
30. Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube.
J Pathol (2007) 211(1):2635. doi:10.1002/path.2091
31. Callahan MJ, Crum CP, Medeiros F, Kindelberger DW, Elvin JA, Garber JE,
et al. Primary fallopian tube malignancies in BRCA-positive women undergoing
surgery for ovarian ancer risk reduction. J Clin Oncol (2007) 25(25):398590.
doi:10.1200/JCO.2007.12.2622
32. Mingels MJ, Roelofsen T, van der Laak JA, de Hullu JA, van Ham MA, Massuger LF, et al. Tubal epithelial lesions in salpingo-oophorectomy specimens
of BRCA-mutation carriers and controls. Gynecol Oncol (2012) 127(1):8893.
doi:10.1016/j.ygyno.2012.06.015
33. Reitsma W, de Bock GH, Oosterwijk JC, Bart J, Hollema H, Mourits MJ.
Support of the fallopian tube hypothesis in a prospective series of riskreducing salpingo-oophorectomy specimens. Eur J Cancer (2013) 49(1):13241.
doi:10.1016/j.ejca.2012.07.021
34. Salvador S, Gilks B, Kbel M, Huntsman D, Rosen B, Miller D. The fallopian
tube: primary site of most pelvic high-grade serous carcinomas. Int J Gynecol
Cancer (2009) 19(1):5864. doi:10.1111/IGC.0b013e318199009c
35. Reade CJ, Finlayson S, McAlpine J, Tone AA, Fung-Kee-Fung M, Ferguson SE.
Risk-reducing salpingectomy in Canada: a survey of obstetrician-gynaecologists.
J Obstet Gynaecol Can (2013) 35(7):62734.
36. Kamran MW, Vaughan D, Crosby D, Wahab NA, Saadeh FA, Gleeson N. Opportunistic and interventional salpingectomy in women at risk: a strategy for preventing pelvic serous cancer (PSC). Eur J Obstet Gynecol Reprod Biol (2013)
170(1):2514. doi:10.1016/j.ejogrb.2013.06.030
37. Plusquin C, Fastrez M, Vandromme J, Rozenberg S. Factors affecting gynaecologists decision to perform prophylactic oophorectomy concomitantly with
hysterectomy: a Belgian survey. Maturitas (2011) 70(4):3914. doi:10.1016/j.
maturitas.2011.09.007
38. Morelli M, Venturella R, Mocciaro R, Di Cello A, Rania E, Lico D, et al. Prophylactic salpingectomy in premenopausal low-risk women for ovarian cancer:
primum non nocere. Gynecol Oncol (2013) 129(3):44851. doi:10.1016/j.ygyno.
2013.03.023
39. Collins IM, Domchek SM, Huntsman DG, Mitchell G. The tubal hypothesis of ovarian cancer: caution needed. Lancet Oncol (2011) 12(12):108991.
doi:10.1016/S1470-2045(11)70222-4
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 30 September 2013; accepted: 26 January 2014; published online: 10 February
2014.
Citation: Schenberg T and Mitchell G (2014) Prophylactic bilateral salpingectomy as
a prevention strategy in women at high-risk of ovarian cancer: a mini-review. Front.
Oncol. 4:21. doi: 10.3389/fonc.2014.00021
This article was submitted to Womens Cancer, a section of the journal Frontiers in
Oncology.
Copyright 2014 Schenberg and Mitchell. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s)
or licensor are credited and that the original publication in this journal is cited, in
accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.